- Home
- CRMD vs OVID Comparison
CRMD vs OVID Comparison
Compare CRMD & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | OVID |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.7M | 562.5M |
| IPO Year | 2009 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRMD | OVID |
|---|---|---|
| Price | $7.75 | $2.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $15.33 | $6.00 |
| AVG Volume (30 Days) | 936.1K | ★ 1.6M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | 3.90 |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $311,709,000.00 | $7,252,000.00 |
| Revenue This Year | $8.13 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | 617.03 | ★ 1181.27 |
| 52 Week Low | $6.13 | $1.18 |
| 52 Week High | $13.02 | $3.11 |
Technical Indicators
Market Signals| Indicator | CRMD | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 58.79 |
| Support Level | $7.08 | $2.56 |
| Resistance Level | $9.01 | $2.87 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 97.18 | 96.79 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.